LT2895509T - T ląstelių receptoriai, atpažįstantys mhc ii klasės apribotą mage-a3 - Google Patents

T ląstelių receptoriai, atpažįstantys mhc ii klasės apribotą mage-a3

Info

Publication number
LT2895509T
LT2895509T LTEP13767200.2T LT13767200T LT2895509T LT 2895509 T LT2895509 T LT 2895509T LT 13767200 T LT13767200 T LT 13767200T LT 2895509 T LT2895509 T LT 2895509T
Authority
LT
Lithuania
Prior art keywords
mhc class
cell receptors
receptors recognizing
restricted mage
recognizing mhc
Prior art date
Application number
LTEP13767200.2T
Other languages
English (en)
Inventor
Paul F. Robbins
Steven A. Rosenberg
Xin Yao
Original Assignee
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The U.S.A. As Represented By The Secretary, Department Of Health And Human Services filed Critical The U.S.A. As Represented By The Secretary, Department Of Health And Human Services
Publication of LT2895509T publication Critical patent/LT2895509T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
LTEP13767200.2T 2012-09-14 2013-09-13 T ląstelių receptoriai, atpažįstantys mhc ii klasės apribotą mage-a3 LT2895509T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261701056P 2012-09-14 2012-09-14
PCT/US2013/059608 WO2014043441A1 (en) 2012-09-14 2013-09-13 T cell receptors recognizing mhc class ii-restricted mage-a3

Publications (1)

Publication Number Publication Date
LT2895509T true LT2895509T (lt) 2020-03-25

Family

ID=49253425

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13767200.2T LT2895509T (lt) 2012-09-14 2013-09-13 T ląstelių receptoriai, atpažįstantys mhc ii klasės apribotą mage-a3

Country Status (19)

Country Link
US (4) US9879065B2 (lt)
EP (3) EP3636665B1 (lt)
JP (4) JP6461796B2 (lt)
KR (4) KR102370307B1 (lt)
CN (2) CN104968675B (lt)
AU (4) AU2013315391B2 (lt)
CA (1) CA2884743C (lt)
CY (1) CY1122720T1 (lt)
DK (2) DK3636665T3 (lt)
ES (2) ES2925307T3 (lt)
HR (1) HRP20200325T1 (lt)
HU (1) HUE048014T2 (lt)
IL (3) IL286786B (lt)
LT (1) LT2895509T (lt)
MX (2) MX367279B (lt)
PL (1) PL2895509T3 (lt)
PT (1) PT2895509T (lt)
SI (1) SI2895509T1 (lt)
WO (1) WO2014043441A1 (lt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107075479A (zh) 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞的方法
CA2963362A1 (en) * 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
DK3388075T5 (da) * 2015-03-27 2024-09-23 Immatics Biotechnologies Gmbh Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
EP3416668A4 (en) 2016-02-18 2020-02-19 The Wistar Institute Of Anatomy And Biology METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
GB201604494D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
LT3430037T (lt) 2016-03-16 2022-12-12 Immatics Biotechnologies Gmbh Transfekuotos t ląstelės ir t ląstelių receptoriai, skirti naudoti vėžio gydymui taikant imunoterapiją
CN106749620B (zh) * 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 识别mage-a1抗原短肽的t细胞受体
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2018097951A1 (en) 2016-11-22 2018-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3/a6 antibodies
DE102016123859B3 (de) 2016-12-08 2018-03-01 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
CN108250289B (zh) * 2016-12-28 2021-10-08 香雪生命科学技术（广东）有限公司 源自于mage b6的肿瘤抗原短肽
EP3565535A4 (en) 2017-01-05 2020-12-30 Fred Hutchinson Cancer Research Center SYSTEMS AND METHODS FOR IMPROVING THE EFFECTIVENESS OF A VACCINE
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
CN111417720A (zh) * 2017-10-05 2020-07-14 美国卫生和人力服务部 用于选择性扩增表达具有鼠恒定区的tcr的细胞的方法
US20200316122A1 (en) 2017-10-11 2020-10-08 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of producing t cell populations using p38 mapk inhibitors
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
CN109836490A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向mage-a3的t细胞受体、t细胞受体基因修饰t细胞及其制备方法和应用
CN109837248A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种tcr敲除的靶向mage-a3的t细胞受体基因修饰t细胞及其制备方法和应用
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
EP3749770A1 (en) 2018-02-09 2020-12-16 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Tethered interleukin-15 and interleukin-21
KR20210003767A (ko) * 2018-04-19 2021-01-12 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Mage-b2 특이성을 갖는 t 세포 수용체 및 이의 용도
EP3784774A1 (en) 2018-04-24 2021-03-03 The United States of America, as represented by the Secretary, Department of Health and Human Services Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
AU2020315325A1 (en) * 2019-07-15 2022-02-17 Neogene Therapeutics B.V. Method to isolate TCR genes
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
JP2020143057A (ja) * 2020-04-01 2020-09-10 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
AU2021341969A1 (en) 2020-09-08 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell phenotypes associated with response to adoptive cell therapy
EP4243937A2 (en) 2020-11-13 2023-09-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
WO2023130040A2 (en) 2021-12-31 2023-07-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell therapy with vaccination as a combination immunotherapy against cancer
CN116813744B (zh) * 2023-02-23 2024-02-23 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IN165717B (lt) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
JP2013535199A (ja) 2010-07-28 2013-09-12 イムノコア リミテッド Ｔ細胞レセプター
AU2011304728A1 (en) * 2010-09-20 2013-03-14 Biontech Ag Antigen-specific T cell receptors and T cell epitopes
WO2012054825A1 (en) * 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
PT2755997T (pt) 2011-09-15 2018-10-30 Us Health Recetores de célula t que reconhecem mage restrito a hlaa1 ou hla-cw7
US9413985B2 (en) * 2012-09-12 2016-08-09 Lattice Semiconductor Corporation Combining video and audio streams utilizing pixel repetition bandwidth

Also Published As

Publication number Publication date
CY1122720T1 (el) 2021-03-12
JP6728326B2 (ja) 2020-07-22
JP6923714B2 (ja) 2021-08-25
ES2774931T3 (es) 2020-07-23
CN104968675A (zh) 2015-10-07
WO2014043441A1 (en) 2014-03-20
AU2019213329B2 (en) 2021-03-11
EP2895509B1 (en) 2019-12-04
MX367279B (es) 2019-08-13
US20150246959A1 (en) 2015-09-03
DK2895509T3 (da) 2020-03-09
DK3636665T3 (da) 2022-10-03
EP4159753A1 (en) 2023-04-05
MX2015003061A (es) 2015-11-06
EP3636665B1 (en) 2022-06-29
KR20220031941A (ko) 2022-03-14
MX2019009641A (es) 2019-11-28
SI2895509T1 (sl) 2020-04-30
US20230089465A1 (en) 2023-03-23
AU2021203746B2 (en) 2024-05-02
AU2021203746A1 (en) 2021-07-01
HUE048014T2 (hu) 2020-05-28
CN113754755A (zh) 2021-12-07
JP2021191265A (ja) 2021-12-16
JP2015535816A (ja) 2015-12-17
CA2884743C (en) 2023-03-14
KR20150052086A (ko) 2015-05-13
IL274003B (en) 2021-10-31
KR20210114563A (ko) 2021-09-23
US20180127479A1 (en) 2018-05-10
CN104968675B (zh) 2021-09-24
AU2013315391B2 (en) 2017-06-08
KR102370307B1 (ko) 2022-03-04
JP6461796B2 (ja) 2019-01-30
AU2017219019B2 (en) 2019-05-09
US20200270329A1 (en) 2020-08-27
KR20200118248A (ko) 2020-10-14
PT2895509T (pt) 2020-03-13
CA2884743A1 (en) 2014-03-20
EP3636665A1 (en) 2020-04-15
KR102303166B1 (ko) 2021-09-17
US9879065B2 (en) 2018-01-30
KR102165350B1 (ko) 2020-10-14
IL286786B (en) 2022-09-01
EP2895509A1 (en) 2015-07-22
ES2925307T3 (es) 2022-10-14
AU2019213329A1 (en) 2019-08-29
IL286786A (en) 2021-10-31
PL2895509T3 (pl) 2020-07-27
US10611815B2 (en) 2020-04-07
KR102480188B1 (ko) 2022-12-21
HRP20200325T1 (hr) 2020-06-12
IL237560B (en) 2020-05-31
IL274003A (en) 2020-05-31
IL237560A0 (en) 2015-04-30
AU2013315391A1 (en) 2015-04-02
AU2017219019A1 (en) 2017-09-14
JP7270001B2 (ja) 2023-05-09
JP2019088286A (ja) 2019-06-13
JP2020178702A (ja) 2020-11-05

Similar Documents

Publication Publication Date Title
IL286786A (en) T cell receptors that recognize mhc mage–a3 are restricted type ii
IL290105A (en) Mage-recognizing t cell receptors are restricted to 1hla–a or hla–cw7
HK1251874A1 (zh) 鼠抗-ny-eso-1 t細胞受體
HK1222338A1 (zh) 細胞受體
HK1211039A1 (en) Engineering -cell receptors
HK1221724A1 (zh) 細胞受體
IL235355B (en) A method for creating receptors for t cells
EP2814104A4 (en) ZINC RECHARGEABLE BATTERY
EP2911230A4 (en) CELL
GB201322430D0 (en) T cell receptors
IL238745B (en) Electrochemical separation device
GB201201418D0 (en) T Cell receptors
GB201218496D0 (en) Cell
TH1301006465B (th) แบตเตอรี่ตะกั่ว